JP2020521447A5 - - Google Patents

Download PDF

Info

Publication number
JP2020521447A5
JP2020521447A5 JP2019564782A JP2019564782A JP2020521447A5 JP 2020521447 A5 JP2020521447 A5 JP 2020521447A5 JP 2019564782 A JP2019564782 A JP 2019564782A JP 2019564782 A JP2019564782 A JP 2019564782A JP 2020521447 A5 JP2020521447 A5 JP 2020521447A5
Authority
JP
Japan
Prior art keywords
drawings
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019564782A
Other languages
English (en)
Other versions
JP2020521447A (ja
JP7522426B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/034655 external-priority patent/WO2018218151A1/en
Publication of JP2020521447A publication Critical patent/JP2020521447A/ja
Publication of JP2020521447A5 publication Critical patent/JP2020521447A5/ja
Priority to JP2024109160A priority Critical patent/JP2024133640A/ja
Application granted granted Critical
Publication of JP7522426B2 publication Critical patent/JP7522426B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (1)

  1. 明細書または図面に記載の発明。
JP2019564782A 2017-05-25 2018-05-25 天然キラー細胞による殺傷に対する腫瘍細胞の感受性を高めるための新規な腫瘍溶解性ウイルス Active JP7522426B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024109160A JP2024133640A (ja) 2017-05-25 2024-07-05 天然キラー細胞による殺傷に対する腫瘍細胞の感受性を高めるための新規な腫瘍溶解性ウイルス

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762511010P 2017-05-25 2017-05-25
US62/511,010 2017-05-25
PCT/US2018/034655 WO2018218151A1 (en) 2017-05-25 2018-05-25 Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024109160A Division JP2024133640A (ja) 2017-05-25 2024-07-05 天然キラー細胞による殺傷に対する腫瘍細胞の感受性を高めるための新規な腫瘍溶解性ウイルス

Publications (3)

Publication Number Publication Date
JP2020521447A JP2020521447A (ja) 2020-07-27
JP2020521447A5 true JP2020521447A5 (ja) 2021-07-26
JP7522426B2 JP7522426B2 (ja) 2024-07-25

Family

ID=64397136

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019564782A Active JP7522426B2 (ja) 2017-05-25 2018-05-25 天然キラー細胞による殺傷に対する腫瘍細胞の感受性を高めるための新規な腫瘍溶解性ウイルス
JP2024109160A Pending JP2024133640A (ja) 2017-05-25 2024-07-05 天然キラー細胞による殺傷に対する腫瘍細胞の感受性を高めるための新規な腫瘍溶解性ウイルス

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024109160A Pending JP2024133640A (ja) 2017-05-25 2024-07-05 天然キラー細胞による殺傷に対する腫瘍細胞の感受性を高めるための新規な腫瘍溶解性ウイルス

Country Status (10)

Country Link
US (2) US11684637B2 (ja)
EP (1) EP3630144A4 (ja)
JP (2) JP7522426B2 (ja)
KR (2) KR20240132124A (ja)
CN (1) CN110891584B (ja)
AU (1) AU2018273963B2 (ja)
BR (1) BR112019024656A2 (ja)
CA (1) CA3064897A1 (ja)
IL (1) IL270876B2 (ja)
WO (1) WO2018218151A1 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
GB2597623A (en) 2017-08-07 2022-02-02 Univ California Platform for generating safe cell therapeutics
JP2022518262A (ja) * 2019-01-24 2022-03-14 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド ナチュラルキラー細胞を刺激するための組成物及び方法
MX2022006319A (es) * 2019-11-25 2022-10-27 Ansun Biopharma Inc Suministro de celulas inmunitarias de sialidasa a celulas cancerosas, celulas inmunitarias y microambiente tumoral.
CN111676245B (zh) * 2020-06-24 2022-09-13 武汉波睿达生物科技有限公司 一种含有HSV-1型溶瘤病毒的NFAT-Cre-CAR-T细胞及其应用
CN112852757A (zh) * 2021-02-01 2021-05-28 南京大学 一种制备新型溶瘤病毒EM/VSV-G Ad5sPVRCD137L的方法
EP4319778A1 (en) * 2021-04-08 2024-02-14 Immvira Biopharmaceuticals Co., Limited Genetically modified oncolytic herpes simplex virus delivering chemokine and tumor associated/specific antigen
CN116875547A (zh) * 2023-09-04 2023-10-13 山东德升细胞治疗工程技术有限公司 一种利用细胞外泌体激活nk细胞的体外扩增培养方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (ja) 1968-10-17 1970-08-24
US20020187543A1 (en) * 2001-04-05 2002-12-12 Curiel David T. Enhanced dispersion of adenoviral vectors by fusogenic membrane glycoproteins
US20090214590A1 (en) * 2005-07-08 2009-08-27 Wayne State University Virus Vaccines Comprising Envelope-Bound Immunomodulatory Proteins and Methods of Use Thereof
US20080299137A1 (en) 2005-10-28 2008-12-04 Novo Nordisk A/S Fusion Proteins That Bind Effector Lymphocytes And Target Cells
WO2008067305A2 (en) 2006-11-28 2008-06-05 Giic Research Development Corporation Polypeptides comprising intracytoplasmic death domain and nkg2d ligand domain
WO2008140603A2 (en) * 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
WO2008140621A2 (en) * 2006-12-21 2008-11-20 Mount Sinai School Of Medicine Of New York University Transgenic oncolytic viruses and uses thereof
FR2938840B1 (fr) 2008-11-21 2010-12-17 Centre Nat Rech Scient Proteines mutantes de la proteine f de piv-5 et de piv-2
CA2748180C (en) 2008-12-22 2017-06-20 Oncos Therapeutics Oy Oncolytic adenoviral vectors and methods and uses related thereto
EP2485758A1 (en) * 2009-10-09 2012-08-15 New York Blood Center, Inc. Immunopotentiator-linked oligomeric influenza immunogenic compositions
CN108130345A (zh) * 2012-01-24 2018-06-08 乔治亚大学研究基金公司 基于副流感病毒5的疫苗
RS64172B1 (sr) * 2012-06-28 2023-05-31 Univ Of Central Florida Research Foundation Incorporated Postupci i kompozicije za ćelije prirodne ubice
EP2892549A1 (en) * 2012-09-04 2015-07-15 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
WO2014041119A1 (en) * 2012-09-14 2014-03-20 Deutsches Krebsforschungszentrum Oncolytic viruses expressing immuno-nucleases
NZ711946A (en) 2013-03-14 2020-05-29 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
WO2015069745A2 (en) 2013-11-05 2015-05-14 The Board Of Regents Of The University Of Texas System Tumors expressing igg1 fc induce robust cd8 cell responses
US10238700B2 (en) * 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
CA2960087C (en) 2014-09-26 2024-02-27 Bavarian Nordic A/S Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin
SG11201703397UA (en) * 2014-10-27 2017-05-30 Univ Central Florida Res Found Methods and compositions for natural killer cells
WO2016109668A1 (en) * 2014-12-31 2016-07-07 Anthrogenesis Corporation Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
RU2752918C2 (ru) * 2015-04-08 2021-08-11 Новартис Аг Cd20 терапия, cd22 терапия и комбинированная терапия клетками, экспрессирующими химерный антигенный рецептор (car) k cd19
MX2017013684A (es) * 2015-04-30 2018-08-28 Psioxus Therapeutics Ltd Adenovirus oncolitico que codifica una proteina b7.
WO2018083259A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes

Similar Documents

Publication Publication Date Title
JP2019030304A5 (ja)
JP2020530297A5 (ja)
JP2020042034A5 (ja)
JP2021502066A5 (ja)
JP2022028828A5 (ja)
JP2022025124A5 (ja)
JP2021185136A5 (ja)
JP2021169491A5 (ja)
JP2020534795A5 (ja)
JP2021500894A5 (ja)
JP2020040981A5 (ja)
JP2020007340A5 (ja)
JP2021503478A5 (ja)
JP2018154848A5 (ja)
JP2021028398A5 (ja)
JP2019068846A5 (ja)
JP2020127428A5 (ja)
JP2019536002A5 (ja)
JP2017214405A5 (ja)
JP2016196495A5 (ja)
JP2018135352A5 (ja)
JP2021038271A5 (ja)
JP2018111825A5 (ja)
JP2020010717A5 (ja)
JP2019142968A5 (ja)